series c+
Stage
2017
Founded
3
Investors
About
Fore Biotherapeutics is a virtual biotechnology company developing plixorafenib, a next-generation BRAF inhibitor designed to target a broad range of BRAF alterations in advanced solid tumors. The company is advancing plixorafenib in the global FORTE Phase 2 registration-intended clinical trial.
Explore Fore Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.